Thorac Cardiovasc Surg 2020; 68(03): 212-218
DOI: 10.1055/s-0039-1691748
Review
Georg Thieme Verlag KG Stuttgart · New York

Topical Use of Tranexamic Acid in Cardiac Surgery: A Meta-Analysis

Louay M. Habbab
1   Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
,
Lloyd Semelhago
1   Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
,
André Lamy
1   Division of Cardiac Surgery, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

20 January 2019

12 April 2019

Publication Date:
06 June 2019 (online)

Abstract

Background This meta-analysis was conducted to investigate the evidence for the efficacy and safety of intrapericardial tranexamic acid (TXA) in cardiac surgery.

Methods We searched MEDLINE from 2000 to 2017 for randomized controlled trials that compared intrapericardial TXA to placebo. We performed a meta-analysis for the eligible trials that focused on chest tube drainage measured during the first 24 hours after surgery as a primary outcome. We also examined the secondary outcome measures of these trials such as the incidence of transfusion requirements following surgery and the evidence for any increase in complication rates.

Results A total of seven randomized controlled trials (six on-pump and one off-pump) comparing topical application of TXA to placebo in 692 patients were eligible for the blood loss outcome data. These trials randomized 372 patients to receive TXA and 320 patients as controls. The use of intrapericardial TXA was associated with a considerable reduction in 24-hour blood loss in all seven studies and a weighted mean difference of −343.56 mL (95% confidence interval: −316.41, −370.72) significantly differed from zero (p = 0.005) with a heterogeneity of I 2 = 0%. The incidence of packed RBC transfusion in TXA patients was significantly lower in one study and was not significant but with trend in favor of TXA in five out of the six studies in which it was reported. In one trial, TXA was not detected in any patient and in another the studied groups were similar in postoperative complications, such as graft patency, myocardial infarction, cerebral infarction, atrial fibrillation, seizures, and infections.

Conclusions Findings from this meta-analysis suggest that intrapericardial use of TXA in patients undergoing cardiac surgery can decrease postoperative bleeding without increasing the risk of postoperative seizures. Future large randomized, double-blind, controlled clinical trials are needed to confirm these promising findings.

 
  • References

  • 1 Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol 1986; 23 (03) 223-229
  • 2 Harker LA, Malpass TW, Branson HE, Hessel II EA, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56 (05) 824-834
  • 3 Despotis GJ, Santoro SA, Spitznagel E. , et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107 (01) 271-279
  • 4 Lemmer Jr JH, Stanford W, Bonney SL. , et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107 (02) 543-551 , discussion 551–553
  • 5 Santos AT, Kalil RA, Bauemann C, Pereira JB, Nesralla IA. A randomized, double-blind, and placebo-controlled study with tranexamic acid of bleeding and fibrinolytic activity after primary coronary artery bypass grafting. Braz J Med Biol Res 2006; 39 (01) 63-69
  • 6 Pleym H, Stenseth R, Wahba A, Bjella L, Karevold A, Dale O. Single-dose tranexamic acid reduces postoperative bleeding after coronary surgery in patients treated with aspirin until surgery. Anesth Analg 2003; 96 (04) 923-928
  • 7 Ferraris VA, Brown JR, Despotis GJ. , et al; Society of Thoracic Surgeons Blood Conservation Guideline Task Force; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion; International Consortium for Evidence Based Perfusion. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91 (03) 944-982
  • 8 Myles PS, Smith JA, Kasza J. , et al; ATACAS investigators and the ANZCA Clinical Trials Network. Tranexamic acid in coronary artery surgery: one-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial. J Thorac Cardiovasc Surg 2019; 157 (02) 644.e9-652.e9
  • 9 Ross J, Al-Shahi Salman R. The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf 2012; 7 (01) 44-54
  • 10 Myles PS, Smith JA, Forbes A. , et al; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376 (02) 136-148
  • 11 Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008; 107 (06) 1783-1790
  • 12 Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg 2012; 93 (01) 148-154
  • 13 Furtmüller R, Schlag MG, Berger M. , et al. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301 (01) 168-173
  • 14 Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 2009; 56 (03) 202-212
  • 15 Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29 (03) 236-261
  • 16 Valsecchi A. Further notes on the topical use of tranexamic acid in the treatment of gynecological hemorrhage [in Italian]. Minerva Ginecol 1980; 32 (09) 825-830
  • 17 Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989; 320 (13) 840-843
  • 18 Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 2012; 470 (09) 2605-2612
  • 19 Goyal N, Chen DB, Harris IA, Rowden NJ, Kirsh G, MacDessi SJ. Intravenous vs intra-articular tranexamic acid in total knee arthroplasty: a randomized, double-blind trial. J Arthroplasty 2017; 32 (01) 28-32
  • 20 Patel JN, Spanyer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study. J Arthroplasty 2014; 29 (08) 1528-1531
  • 21 De Bonis M, Cavaliere F, Alessandrini F. , et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 2000; 119 (03) 575-580
  • 22 Abul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol 2006; 23 (05) 380-384
  • 23 Baric D, Biocina B, Unic D. , et al. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorac Surg 2007; 31 (03) 366-371 , discussion 371
  • 24 Fawzy H, Elmistekawy E, Bonneau D, Latter D, Errett L. Can local application of tranexamic acid reduce post-coronary bypass surgery blood loss? A randomized controlled trial. J Cardiothorac Surg 2009; 4: 25
  • 25 Aoki M, Okawa Y, Goto Y, Ogawa S, Baba H. Local administration of tranexamic acid in off-pump coronary artery bypass. Asian Cardiovasc Thorac Ann 2012; 20 (06) 658-662
  • 26 Hosseini H, Rahimianfar AA, Abdollahi MH. , et al. Evaluations of topical application of tranexamic acid on post-operative blood loss in off-pump coronary artery bypass surgery. Saudi J Anaesth 2014; 8 (02) 224-228
  • 27 Ali Shah MU, Asghar MI, Siddiqi R, Chaudhri MS, Janjua AM, Iqbal A. Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact?. J Coll Physicians Surg Pak 2015; 25 (03) 161-165
  • 28 Spegar J, Vanek T, Snircova J. , et al. Local and systemic application of tranexamic acid in heart valve surgery: a prospective, randomized, double blind LOST study. J Thromb Thrombolysis 2011; 32 (03) 303-310
  • 29 Taman HI, Amer GF, Amera SA. Can topical administration of tranexamic acid be a good adjuvant to the intravenous route for decreasing postoperative seizure incidence? A double blinded randomized study. Ain-Shams J Anaesthesiol 2015; 08: 36-42
  • 30 Vaněk T, Straka Z. Topical use of tranexamic acid in cardiac surgery—a review and meta-analysis of four randomized controlled trials. Cor Vasa 2013; 55: e184-e189
  • 31 Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg 2010; 37 (06) 1375-1383
  • 32 Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180 (02) 183-193
  • 33 Alderman EL, Levy JH, Rich JB. , et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116 (05) 716-730
  • 34 Moreno R, Waxman S, Rowe K, Verrier RL. Intrapericardial beta-adrenergic blockade with esmolol exerts a potent antitachycardic effect without depressing contractility. J Cardiovasc Pharmacol 2000; 36 (06) 722-727
  • 35 Kolettis TM, Kazakos N, Katsouras CS. , et al. Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine. Int J Cardiol 2005; 99 (03) 415-421
  • 36 Habbab LM, Chu FV. Intrapericardial amiodarone for the prevention of postoperative atrial fibrillation. J Card Surg 2016; 31 (04) 253-258
  • 37 Slight RD, Bappu NJ, Nzewi OC, McClelland DB, Mankad PS. Perioperative red cell, plasma, and blood volume change in patients undergoing cardiac surgery. Transfusion 2006; 46 (03) 392-397
  • 38 Hoffmann H, Siebeck M, Thetter O, Jochum M, Fritz H. Aprotinin concentrations effective for the inhibition of tissue kallikrein and plasma kallikrein in vitro and in vivo. Adv Exp Med Biol 1989; 247B: 35-42
  • 39 Ciçek S, Theodoro DA. Topical aprotinin in cardiac operations: a note of caution. Ann Thorac Surg 1996; 61 (03) 1039-1040
  • 40 Jimenez JJ, Iribarren JL, Lorente L. , et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care 2007; 11 (06) R117
  • 41 O'Regan DJ, Giannopoulos N, Mediratta N. , et al. Topical aprotinin in cardiac operations. Ann Thorac Surg 1994; 58 (03) 778-781